A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET) - ND

OVARTIS FARMA0 个研究点目标入组 392 人开始时间: 2007年7月12日最近更新: 2014年6月30日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: OVARTIS FARMA
入组人数: 392

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Key 1. Advanced (unresectable or metastatic) biopsy-proven pancreatic NET patients. 2. Patients must have confirmed low-grade or intermediate-grade neuroendocrine carcinoma. 3. Patients must have radiological documentation of progression of disease within 12 months prior to randomization. If patients received anti-tumor therapy during the past 12 months, they must have radiological documentation of progression of disease while on or after receiving the therapy. 4. Measurable disease per RECIST criteria using Triphasic Computed Tomography (CT) scan or multiphasic MRI for radiologic assessment. 5. Adequate bone marrow function as shown by: ANC >= 1.5 x 109/L, Platelets >= 100 x 109/L, Hemoglobin >9 g/dL. 6. Adequate liver function as shown by: Serum bilirubin <= 1.5 x ULN. INR < 1.3 (INR < 3 in patients treated with anticoagulants) ALT and AST <= 2.5 x ULN (<= 5x ULN in patients with liver metastases). 7. Adequate renal function: serum creatinine <= 1.5 x ULN. 8. Fasting serum cholesterol <= 300 mg/dL OR <= 7.75 mmol/L AND fasting triglycerides <= 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication. 9. Performance Status 0-2 on the WHO scale. 10. Adult male or female patients >= 18 years of age. 11. Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and /or urine pregnancy test 48 hours prior to the administration of the first study treatment. 12. Patients who give a written informed consent obtained according to local guidelines.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Key Exclusion criteria : 1. Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma are not eligible. 2. Cytotoxic chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to randomization. within 4 weeks prior to randomization. 3. Hepatic artery embolization within the last 6 months (1 month if there are other sites of measurable disease), or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of enrollment. 4. Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus). 5. Uncontrolled diabetes mellitus as defined by fasting serum glucose > 1.5 x ULN. 6. Patients who have any severe and/or uncontrolled medical conditions such as: unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction <= 6 months prior to randomization, serious uncontrolled cardiac arrhythmia. active or uncontrolled severe infection. cirrhosis, chronic active hepatitis or chronic persistent hepatitis. severely impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air). active, bleeding diathesis 7. Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent. 8. Patients with a known history of HIV seropositivity. 9. No other prior or concurrent malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, or other adequately treated in situ cancer, or any other cancer from which the patient has been disease free for >= 3 years. 10. Female patients who are pregnant or nursing (lactating), or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes.

研究者

发起方

OVARTIS FARMA

相似试验

进行中（未招募）

1 期

EUCTR2006-006819-75-BEovartis Pharma Services AG392

进行中（未招募）

不适用

A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET) - N/APancreatic neuroendocrine tumors(also called pancreatic endocrine tumors or islet cell tumors (ICT))MedDRA version: 9.1Level: LLTClassification code 10033630Term: Pancreatic islet cell neoplasm malignant NOS

EUCTR2006-006819-75-FRovartis Pharma Services AG392

进行中（未招募）

1 期

EUCTR2006-006819-75-SKovartis Pharma Services AG392

进行中（未招募）

不适用

EUCTR2006-006819-75-GRovartis Pharma Services AG392

进行中（未招募）

1 期

EUCTR2006-006819-75-GBovartis Pharma Services AG410